nach oben

Erschienen in:

05.09.2023 | Original Communication

Investigating differences in young- and late-onset progressive supranuclear palsy

verfasst von: Batoul A. AlWazan, Indira Garcia-Cordero, Blas Couto, Marta Lamartine Monteiro, Michelle Y. Tsang, Jeffrey Antwi, Jonathan Sasitharan, Puja Bhakta, Gabor G. Kovacs, Susan Fox, David F. Tang-Wai, Anthony E. Lang, Maria Carmela Tartaglia

Erschienen in: Journal of Neurology | Ausgabe 12/2023

Einloggen, um Zugang zu erhalten

Abstract

Background

The impact of age of onset on the presentation of progressive supranuclear palsy phenotypes is not well studied. We hypothesized that there is difference in presentation and phenotype between young- and late-onset PSP.

Objectives

Our aim was to compare phenotypes and rate of change in disability between young-onset PSP (YOPSP) and late-onset PSP (LOPSP).

Methods

Retrospective data of patients seen in the Rossy PSP Centre from March 2014 to April 2022 with clinical diagnosis of PSP as per the MDS 2017 diagnostic criteria were examined. We used cut-off age of 65 years to categorize the patients into YOPSP and LOPSP. We compared the prevalence of phenotypes, presenting symptoms, and MDS core criteria between the two groups. The severity of disease between the two groups was measured using PSP-RS.

Results

We found 107 patients with clinical diagnosis of PSP as per MDS criteria, a third were defined as YOPSP. PSP speech/language (SL) phenotype was more prevalent in YOPSP (18% vs 0%, p < 0.001). Aphasia was significantly higher in YOPSP (16% vs 1.4%, p = 0.03). The speech and language dysfunction (C1) core criteria were more prevalent in YOPSP (33.3% vs 12.2%, p = 0.05). Longitudinal analysis of PSP-RS showed worsening of bulbar total score at 6 months in YOPSP (t (38) = 2.87; p = 0.05).

Conclusion

Our study revealed that YOPSP are more likely to present with a speech and language variant. Our results highlight that age of onset may predict PSP phenotypes, which holds both clinical and prognostic importance.

Steele JC (1964) Progressive supranuclear palsy. Arch Neurol 10(4):333. https://doi.org/10.1001/archneur.1964.00460160003001CrossRefPubMed

Höglinger GU, Respondek G, Stamelou M et al (2017) Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. Mov Disord 32(6):853–864. https://doi.org/10.1002/mds.26987CrossRefPubMedPubMedCentral

Litvan I, Mangone CA, McKee A et al (1996) Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival: a clinicopathological study. J Neurol Neurosurg Psychiatry 60(6):615–620. https://doi.org/10.1136/jnnp.60.6.615CrossRefPubMedPubMedCentral

Shoeibi A, Litvan I, Tolosa E, del Ser T, Lee E (2019) Progression of two Progressive Supranuclear Palsy phenotypes with comparable initial disability. Parkinsonism Relat Disord 66:87–93. https://doi.org/10.1016/j.parkreldis.2019.07.010CrossRefPubMed

Guasp M, Molina-Porcel L, Painous C et al (2021) Association of PSP phenotypes with survival: a brain-bank study. Parkinsonism Relat Disord 84:77–81. https://doi.org/10.1016/j.parkreldis.2021.01.015CrossRefPubMed

Street D, Malpetti M, Rittman T et al (2021) Clinical progression of progressive supranuclear palsy: impact of trials bias and phenotype variants. Brain Commun. https://doi.org/10.1093/braincomms/fcab206CrossRefPubMedPubMedCentral

The ICD-10 Classification of Mental and Behavioural disorder (1993) https://cdn.who.int/media/docs/default-source/classification/other-classifications/9241544228_eng.pdf. Accessed 15 Dec 2022

Frisoni GB (2005) Structural correlates of early and late onset Alzheimer’s disease: voxel based morphometric study. J Neurol Neurosurg Psychiatry 76(1):112–114. https://doi.org/10.1136/jnnp.2003.029876CrossRefPubMedPubMedCentral

Koedam ELGE, Pijnenburg YAL, Deeg DJH et al (2008) Early-onset dementia is associated with higher mortality. Dement Geriatr Cogn Disord 26(2):147–152. https://doi.org/10.1159/000149585CrossRefPubMed

10.

Palasí A, Gutiérrez-Iglesias B, Alegret M et al (2015) Differentiated clinical presentation of early and late-onset Alzheimer’s disease: is 65 years of age providing a reliable threshold? J Neurol 262(5):1238–1246. https://doi.org/10.1007/s00415-015-7698-3CrossRefPubMed

11.

Sakai M, Hanyu H, Kume K et al (2013) Rate of progression of Alzheimer’s disease in younger versus older patients: a longitudinal single photon emission computed tomography study. Geriatr Gerontol Int 13(3):555–562. https://doi.org/10.1111/j.1447-0594.2012.00934.xCrossRefPubMed

12.

Eriksson H, Fereshtehnejad S-M, Falahati F, Farahmand B, Religa D, Eriksdotter M (2014) Differences in routine clinical practice between early and late onset alzheimer’s disease: data from the Swedish Dementia Registry (SveDem). JAD 41(2):411–419. https://doi.org/10.3233/jad-132273CrossRefPubMed

13.

Koss E, Edland S, Fillenbaum G et al (1996) Clinical and neuropsychological differences between patients with earlier and later onset of Alzheimer’s disease. Neurology 46(1):136–141. https://doi.org/10.1212/wnl.46.1.136CrossRefPubMed

14.

Nochlin D, van Belle G, Bird TD, Sumi SM (1993) Comparison of the severity of neuropathologic changes in familial and sporadic Alzheimer’s disease. Alzheimer’s Dise Assoc Disord 4(7):212–222

15.

Mendez MF, Lee AS, Joshi A, Shapira JS (2012) Nonamnestic presentations of early-onset Alzheimer’s disease. Am J Alzheimers Dis Other Demen 27(6):413–420. https://doi.org/10.1177/1533317512454711CrossRefPubMedPubMedCentral

16.

Phillips ML, Stage EC Jr, Lane KA et al (2019) Neurodegenerative patterns of cognitive clusters of early-onset Alzheimer’s disease subjects: evidence for disease heterogeneity. Dement Geriatr Cogn Disord 48(3–4):131–142. https://doi.org/10.1159/000504341CrossRefPubMed

17.

Seltzer B (1983) A comparison of clinical features in early- and late-onset primary degenerative dementia. Arch Neurol 40(3):143. https://doi.org/10.1001/archneur.1983.04050030037006CrossRefPubMed

18.

Jacobs D, Sano M, Marder K et al (1994) Age at onset of Alzheimer’s disease. Neurology 44(7):1215–1215. https://doi.org/10.1212/wnl.44.7.1215CrossRefPubMed

19.

Rossor MN, Fox NC, Mummery CJ, Schott JM, Warren JD (2010) The diagnosis of young-onset dementia. Lancet Neurol 9(8):793–806. https://doi.org/10.1016/S1474-4422(10)70159-9CrossRefPubMedPubMedCentral

20.

Fieldhouse JLP, Gossink FT, Feenstra TC et al (2021) Clinical phenotypes of behavioral variant frontotemporal dementia by age at onset. Alzheimer’s Dement. https://doi.org/10.1002/alz.053002CrossRef

21.

Jabbari E, Woodside J, Tan MMX et al (2019) The genetic and clinico-pathological profile of early-onset progressive supranuclear palsy. Mov Disord 34(9):1307–1314. https://doi.org/10.1002/mds.27786CrossRefPubMedPubMedCentral

22.

Couto B, Fox S, Tartaglia MC et al (2023) The Rossy Progressive Supranuclear Palsy Centre: creation and initial experience. Can J Neurol Sci. https://doi.org/10.1017/cjn.2022.332CrossRefPubMed

23.

Golbe LI, Ohman-Strickland PA (2007) A clinical rating scale for progressive supranuclear palsy. Brain 130(6):1552–1565. https://doi.org/10.1093/brain/awm032CrossRefPubMed

24.

Gazzina S, Respondek G, Compta Y, et al. Neuropathological validation of the MDS-PSP criteria with PSP and other frontotemporal lobar degeneration. doi: https://doi.org/10.1101/520510

25.

Horta-Barba A, Pagonabarraga J, Martínez-Horta S et al (2021) Cognitive and behavioral profile of progressive supranuclear palsy and its phenotypes. J Neurol. https://doi.org/10.1007/s00415-021-10511-yCrossRefPubMed

26.

Picillo M, Cuoco S, Tepedino MF et al (2019) Motor, cognitive and behavioral differences in MDS PSP phenotypes. J Neurol 266(7):1727–1735. https://doi.org/10.1007/s00415-019-09324-xCrossRefPubMed

27.

Frank A, Peikert K, Linn J, Brandt MD, Hermann A (2020) MDS criteria for the diagnosis of progressive supranuclear palsy overemphasize Richardson syndrome. Ann Clin Transl Neurol 7(9):1702–1707. https://doi.org/10.1002/acn3.51065CrossRefPubMedPubMedCentral

28.

Respondek G, Roeber S, Kretzschmar H et al (2013) Accuracy of the national institute for neurological disorders and stroke/society for progressive supranuclear palsy and neuroprotection and natural history in Parkinson plus syndromes criteria for the diagnosis of progressive supranuclear palsy. Mov Disord 28(4):504–509. https://doi.org/10.1002/mds.25327CrossRefPubMed

29.

Sánchez-Ruiz de Gordoa J, Zelaya V, Tellechea-Aramburo P et al (2022) Is the phenotype designation by PSP-MDS criteria stable throughout the disease course and consistent with tau distribution? Front Neurol. https://doi.org/10.3389/fneur.2022.827338CrossRefPubMedPubMedCentral

30.

Coyle-Gilchrist ITS, Dick KM, Patterson K et al (2016) Prevalence, characteristics, and survival of frontotemporal lobar degeneration syndromes. Neurology 86(18):1736–1743. https://doi.org/10.1212/wnl.0000000000002638CrossRefPubMedPubMedCentral

31.

Respondek G, Stamelou M, Kurz C et al (2014) The phenotypic spectrum of progressive supranuclear palsy: a retrospective multicenter study of 100 definite cases. Mov Disord 29(14):1758–1766. https://doi.org/10.1002/mds.26054CrossRefPubMed

32.

Respondek G, Kurz C, Arzberger T et al (2017) Which ante mortem clinical features predict progressive supranuclear palsy pathology? Mov Disord 32(7):995–1005. https://doi.org/10.1002/mds.27034CrossRefPubMedPubMedCentral

33.

Viscidi E, Litvan I, Dam T et al (2021) Clinical features of patients with progressive supranuclear palsy in an US insurance claims database. Front Neurol. https://doi.org/10.3389/fneur.2021.571800CrossRefPubMedPubMedCentral

34.

Painous C, Martí MJ, Simonet C et al (2020) Prediagnostic motor and non-motor symptoms in progressive supranuclear palsy: The step-back PSP study. Parkinsonism Relat Disord 74:67–73. https://doi.org/10.1016/j.parkreldis.2020.03.003CrossRefPubMed

35.

Seo SW, Thibodeau MP, Perry DC et al (2018) Early vs late age at onset frontotemporal dementia and frontotemporal lobar degeneration. Neurology 90(12):e1047–e1056. https://doi.org/10.1212/WNL.0000000000005163CrossRefPubMedPubMedCentral

36.

Pagano G, Ferrara N, Brooks DJ, Pavese N (2016) Age at onset and Parkinson disease phenotype. Neurology 86(15):1400–1407. https://doi.org/10.1212/WNL.0000000000002461CrossRefPubMedPubMedCentral

37.

Bozi M, Bhatia KP (2003) Paroxysmal exercise-induced dystonia as a presenting feature of young-onset Parkinson’s disease. Mov Disord 18(12):1545–1547. https://doi.org/10.1002/mds.10597CrossRefPubMed

38.

Ferguson LW, Rajput AH, Rajput A (2016) Early-onset vs. Late-onset Parkinson’s disease: a clinical-pathological study. Can J Neurol Sci 43(1):113–119. https://doi.org/10.1017/cjn.2015.244CrossRefPubMed

39.

Tang H, Huang J, Nie K et al (2016) Cognitive profile of Parkinson‘s disease patients: a comparative study between early-onset and late-onset Parkinson’s disease. Int J Neurosci 126(3):227–234. https://doi.org/10.3109/00207454.2015.1010646CrossRefPubMed

40.

Mehanna R, Smilowska K, Fleisher J et al (2022) Age Cutoff for early-onset Parkinson‘s disease: recommendations from the International Parkinson and Movement Disorder Society Task Force on Early Onset Parkinson’s Disease. Movement Disord Clin Pract 9(7):869–878. https://doi.org/10.1002/mdc3.13523CrossRef

41.

Ali F, Martin PR, Botha H et al (2019) Sensitivity and specificity of diagnostic criteria for progressive supranuclear palsy. Mov Disord 34(8):1144–1153. https://doi.org/10.1002/mds.27619CrossRefPubMedPubMedCentral

42.

Shoeibi A, Litvan I, Juncos JL et al (2019) Are the International Parkinson disease and Movement Disorder Society progressive supranuclear palsy (IPMDS-PSP) diagnostic criteria accurate enough to differentiate common PSP phenotypes? Parkinsonism Relat Disord 69:34–39. https://doi.org/10.1016/j.parkreldis.2019.10.012CrossRefPubMedPubMedCentral

Titel: Investigating differences in young- and late-onset progressive supranuclear palsy
verfasst von: Batoul A. AlWazan
Indira Garcia-Cordero
Blas Couto
Marta Lamartine Monteiro
Michelle Y. Tsang
Jeffrey Antwi
Jonathan Sasitharan
Puja Bhakta
Gabor G. Kovacs
Susan Fox
David F. Tang-Wai
Anthony E. Lang
Maria Carmela Tartaglia
Publikationsdatum: 05.09.2023
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Neurology / Ausgabe 12/2023
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-023-11976-9

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Schützt Olivenöl vor dem Tod durch Demenz?

10.05.2024 Morbus Alzheimer Nachrichten

Konsumieren Menschen täglich 7 Gramm Olivenöl, ist ihr Risiko, an einer Demenz zu sterben, um mehr als ein Vierten reduziert – und dies weitgehend unabhängig von ihrer sonstigen Ernährung. Dafür sprechen Auswertungen zweier großer US-Studien.

Bluttest erkennt Parkinson schon zehn Jahre vor der Diagnose

10.05.2024 Parkinson-Krankheit Nachrichten

Ein Bluttest kann abnorm aggregiertes Alpha-Synuclein bei einigen Menschen schon zehn Jahre vor Beginn der motorischen Parkinsonsymptome nachweisen. Mit einem solchen Test lassen sich möglicherweise Prodromalstadien erfassen und die Betroffenen früher behandeln.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Wartezeit nicht kürzer, aber Arbeit flexibler

Psychotherapie Medizin aktuell

Fünf Jahren nach der Neugestaltung der Psychotherapie-Richtlinie wurden jetzt die Effekte der vorgenommenen Änderungen ausgewertet. Das Hauptziel der Novellierung war eine kürzere Wartezeit auf Therapieplätze. Dieses Ziel wurde nicht erreicht, es gab jedoch positive Auswirkungen auf andere Bereiche.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

Abstract

Background

Objectives

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2023

Neural correlates of transient topographical disorientation: an experimental EEG–MRI case study

How much refractory is ‘refractory status epilepticus’? A retrospective study of treatment strategies and clinical outcomes

Left atrial appendage flow velocity predicts occult atrial fibrillation in cryptogenic stroke: a CRYPTON-ICM registry

Acute vestibular migraine: a ghost diagnosis in patients with acute vertigo

Video case: A new phenotype within the spectrum of functional orofacial movement disorders

Clinical and economic implications of epilepsy management across treatment lines in Spain: a real-life database analysis